首页 正文

In Vitro Functional Validation of an Anti-FREM2 Nanobody for Glioblastoma Cell Targeting

{{output}}
Background/Objectives: Glioblastomas are the most common brain malignancies. Despite the implementation of multimodal therapy, patient life expectancy after diagnosis is barely 12 to 18 months. Glioblastomas are highly heterogeneous at the genetic and epigenet... ...